ANI Pharmaceuticals | ANIP - Selling And Administration Expenses


ANI Pharmaceuticals reported $76.66M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Hikma Pharmaceutical USD 139M 149M Jun/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Novartis USD 3.3B 137M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025